Scholarlink

Objective <p>Regional citrate anticoagulation (RCA) is recommended as the first choice of anticoagulation strategies in continuous renal replacement therapy (CRRT). However, when using calcium-containing replacement fluid, whether RCA can achieve sufficient anticoagulant effect among different CRRT modalities remains unclear.</p> Materials and methods <p>In this open-label, three-arm, randomized trial, AKI patients receiving RCA-CRRT with calcium-containing replacement fluids were randomized to continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemodiafiltration (CVVHDF) groups from 2022 to 2023. The primary outcomes were circuit lifespan and early circuit failure. Secondary endpoints included the safety of the three groups and 30-day all-cause mortality.</p> Results <p>A total of 121 patients were enrolled, with 40 in CVVH group, 40 in CVVHD group, and 41 in CVVHDF group. The circuit lifespan in CVVHDF group (70&#xa0;h, IQR 65–72) was significantly longer than that in CVVHD (47&#xa0;h, IQR 31.5–54) and CVVH group (64&#xa0;h, IQR 46–71) (<i>P</i> &lt; 0.001). Meanwhile, 27 circuits remained patent for 72&#xa0;h (CVVH: 10/40, 25%; CVVHD: 1/40, 2.5%; CVVHDF: 16/41, 39.02%; <i>P</i> = 0.003). A significantly lower incidence of severe venous chamber thrombosis was observed in the CVVHDF group (2.4%, 1/41) relative to the CVVH (5%, 2/40) and CVVHD (50%, 20/40) groups (<i>P</i> &lt; 0.001). Furthermore, early circuit failure (lifespan &lt; 48&#xa0;h) was observed in 35 circuits, occurring significantly more frequently in the CVVHD group (52.5%, 21/40) than in either the CVVH (22.5%, 9/40) or CVVHDF (12.2%, 5/41) groups (<i>P</i> = 0.004).</p> Conclusion <p>Our findings suggested that RCA-CRRT with calcium-containing replacement solution appeared to be safe and effective, with CVVHDF showing potentially prolonged filter survival compared to alternative modalities, which might support its consideration as a possible option in clinical practice.</p> Trial registration <p>This study was registered in the Chinese Clinical Trial Registry (<a href="http://www.chictr.org.cn">www.chictr.org.cn</a>) under the registration number ChiCTR2200061065 on 15 June 2022.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Peiyun Li,
  • Mingpeng Li,
  • Wanhong Yin,
  • Zhifeng Zhou,
  • Ling Zhang

摘要

Objective

Regional citrate anticoagulation (RCA) is recommended as the first choice of anticoagulation strategies in continuous renal replacement therapy (CRRT). However, when using calcium-containing replacement fluid, whether RCA can achieve sufficient anticoagulant effect among different CRRT modalities remains unclear.

Materials and methods

In this open-label, three-arm, randomized trial, AKI patients receiving RCA-CRRT with calcium-containing replacement fluids were randomized to continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemodiafiltration (CVVHDF) groups from 2022 to 2023. The primary outcomes were circuit lifespan and early circuit failure. Secondary endpoints included the safety of the three groups and 30-day all-cause mortality.

Results

A total of 121 patients were enrolled, with 40 in CVVH group, 40 in CVVHD group, and 41 in CVVHDF group. The circuit lifespan in CVVHDF group (70 h, IQR 65–72) was significantly longer than that in CVVHD (47 h, IQR 31.5–54) and CVVH group (64 h, IQR 46–71) (P < 0.001). Meanwhile, 27 circuits remained patent for 72 h (CVVH: 10/40, 25%; CVVHD: 1/40, 2.5%; CVVHDF: 16/41, 39.02%; P = 0.003). A significantly lower incidence of severe venous chamber thrombosis was observed in the CVVHDF group (2.4%, 1/41) relative to the CVVH (5%, 2/40) and CVVHD (50%, 20/40) groups (P < 0.001). Furthermore, early circuit failure (lifespan < 48 h) was observed in 35 circuits, occurring significantly more frequently in the CVVHD group (52.5%, 21/40) than in either the CVVH (22.5%, 9/40) or CVVHDF (12.2%, 5/41) groups (P = 0.004).

Conclusion

Our findings suggested that RCA-CRRT with calcium-containing replacement solution appeared to be safe and effective, with CVVHDF showing potentially prolonged filter survival compared to alternative modalities, which might support its consideration as a possible option in clinical practice.

Trial registration

This study was registered in the Chinese Clinical Trial Registry (www.chictr.org.cn) under the registration number ChiCTR2200061065 on 15 June 2022.